SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-042737
Filing Date
2023-05-24
Accepted
2023-05-24 16:53:32
Documents
13
Period of Report
2023-05-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea179159-8k_adialpharma.htm   iXBRL 8-K 35138
  Complete submission text file 0001213900-23-042737.txt   254025

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE adiww-20230519.xsd EX-101.SCH 3439
3 XBRL DEFINITION FILE adiww-20230519_def.xml EX-101.DEF 26521
4 XBRL LABEL FILE adiww-20230519_lab.xml EX-101.LAB 36430
5 XBRL PRESENTATION FILE adiww-20230519_pre.xml EX-101.PRE 25145
7 EXTRACTED XBRL INSTANCE DOCUMENT ea179159-8k_adialpharma_htm.xml XML 5256
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

IRS No.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 23954877
SIC: 2834 Pharmaceutical Preparations